These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 36566165)

  • 1. Novel therapies in axial spondyloarthritis.
    Bittar M; Mease P
    Best Pract Res Clin Rheumatol; 2022 Dec; 36(4):101811. PubMed ID: 36566165
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Janus Kinase Inhibitors: A New Tool for the Treatment of Axial Spondyloarthritis.
    Paroli M; Caccavale R; Paroli MP; Spadea L; Accapezzato D
    Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674537
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of Axial Spondyloarthritis - Insights into Upadacitinib.
    Braun J; Kiltz U; Baraliakos X
    Drug Des Devel Ther; 2022; 16():3609-3620. PubMed ID: 36268520
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of axial spondyloarthritis: an update.
    Danve A; Deodhar A
    Nat Rev Rheumatol; 2022 Apr; 18(4):205-216. PubMed ID: 35273385
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current treatment and molecular targets for axial spondyloarthritis: Evidence from randomized controlled trials.
    Sen R; Caplan L
    Curr Opin Pharmacol; 2022 Dec; 67():102307. PubMed ID: 36335714
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nonradiographic axial spondyloarthritis: expanding the spectrum of an old disease: A narrative review.
    Magrey M; Schwartzman S; de Peyrecave N; Sloan VS; Stark JL
    Medicine (Baltimore); 2022 Apr; 101(15):e29063. PubMed ID: 35475794
    [TBL] [Abstract][Full Text] [Related]  

  • 7. News in the treatment of axial spondyloarthritis.
    Žurek M; Horák P
    Vnitr Lek; 2022; 68(5):279-284. PubMed ID: 36283817
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BSR and BHPR guideline for the treatment of axial spondyloarthritis (including ankylosing spondylitis) with biologics.
    Hamilton L; Barkham N; Bhalla A; Brittain R; Cook D; Jones G; Mackay K; Marshall D; Marzo-Ortega H; Murphy D; Riddell C; Sengupta R; Siebert S; Van Rossen L; Gaffney K;
    Rheumatology (Oxford); 2017 Feb; 56(2):313-316. PubMed ID: 27558584
    [No Abstract]   [Full Text] [Related]  

  • 9. Treatment overview of axial spondyloarthritis in 2023.
    Baraliakos X; Kiltz U; Kononenko I; Ciurea A
    Best Pract Res Clin Rheumatol; 2023 Sep; 37(3):101858. PubMed ID: 37673758
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Axial Spondyloarthritis: Evolving concepts regarding the disease's diagnosis and treatment.
    Drosos AA; Venetsanopoulou AI; Voulgari PV
    Eur J Intern Med; 2023 Nov; 117():21-27. PubMed ID: 37414646
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of biological DMARDs: a systematic literature review informing the 2022 update of the ASAS-EULAR recommendations for the management of axial spondyloarthritis.
    Webers C; Ortolan A; Sepriano A; Falzon L; Baraliakos X; Landewé RBM; Ramiro S; van der Heijde D; Nikiphorou E
    Ann Rheum Dis; 2023 Jan; 82(1):130-141. PubMed ID: 36270657
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Personalized tapering of tumor necrosis factor inhibitor in axial spondyloarthritis.
    Huang JX; Lee YH; Leong PY; Wei JC
    Int J Rheum Dis; 2024 Jan; 27(1):e15008. PubMed ID: 38140850
    [No Abstract]   [Full Text] [Related]  

  • 13. Treatment With Tumor Necrosis Factor Inhibitors Is Associated With a Time-Shifted Retardation of Radiographic Sacroiliitis Progression in Patients With Axial Spondyloarthritis: 10-Year Results From the German Spondyloarthritis Inception Cohort.
    Torgutalp M; Rios Rodriguez V; Proft F; Protopopov M; Verba M; Rademacher J; Haibel H; Sieper J; Rudwaleit M; Poddubnyy D
    Arthritis Rheumatol; 2022 Sep; 74(9):1515-1523. PubMed ID: 35437900
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment persistence of tumour necrosis factors and IL-17 inhibitors in axial spondyloarthritis: A multi-center comparative analysis.
    Delépine T; Philippe P; Cailliau E; Houvenagel E; Pascart T; Deprez X; Flipo RM; Letarouilly JG
    Joint Bone Spine; 2022 Nov; 89(6):105416. PubMed ID: 35636707
    [No Abstract]   [Full Text] [Related]  

  • 15. Structural progression in axial spondyloarthritis.
    Aouad K; Ziade N; Baraliakos X
    Joint Bone Spine; 2020 Mar; 87(2):131-136. PubMed ID: 31067506
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Axial spondyloarthritis.
    Sieper J; Braun J; Dougados M; Baeten D
    Nat Rev Dis Primers; 2015 Jul; 1():15013. PubMed ID: 27188328
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Axial spondyloarthritis : Update on management based on the interdisciplinary S3 guidelines on axial spondyloarthritis including early forms and ankylosing spondylitis].
    Kiefer D; Braun J; Kiltz U
    Z Rheumatol; 2022 Apr; 81(3):198-204. PubMed ID: 35113204
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-steroidal anti-inflammatory drugs (NSAIDs) for axial spondyloarthritis (ankylosing spondylitis and non-radiographic axial spondyloarthritis).
    Kroon FP; van der Burg LR; Ramiro S; Landewé RB; Buchbinder R; Falzon L; van der Heijde D
    Cochrane Database Syst Rev; 2015 Jul; 2015(7):CD010952. PubMed ID: 26186173
    [TBL] [Abstract][Full Text] [Related]  

  • 19. No Significant Effects of IL-23 on Initiating and Perpetuating the Axial Spondyloarthritis: The Reasons for the Failure of IL-23 Inhibitors.
    Zhang H; Jiang HL; Dai SM
    Front Immunol; 2022; 13():818413. PubMed ID: 35222393
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Etanercept for the treatment of non-radiographic axial spondyloarthritis.
    Rios Rodriguez V; Poddubnyy D
    Expert Rev Clin Immunol; 2016; 12(5):493-500. PubMed ID: 26788837
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.